Latest news and press releases about Seres Therapeutics, Inc. (MCRB): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI).
Price
| Price | $4.21 |
| Market Cap | $41M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.32 |
| EV / EBITDA | -2.17 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -60.32% |
| Return on Invested Capital | -89.99% |
| Return on Assets | -22.11% |
| Gross Margin | 82.58% |
| Operating Margin | -4462.77% |
| Net Margin | -1192.94% |
Related companies: ABOS · ACTU · APLT · CGTX · HURA · INO · IRD
Explore sector: Healthcare · Biotechnology
More sections of MCRB: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks